secwatch / observer
8-K filed December 15, 2023, 6:59 PM ET ticker GYRE CIK 0001124105
leadership confidence high sentiment neutral materiality 0.70

Gyre Therapeutics appoints Dr. Han Ying as CEO effective Jan 15, 2024; Dr. Charles Wu retires for health reasons

GYRE THERAPEUTICS, INC.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Han Ying

Chief Executive Officer
GYRE · GYRE THERAPEUTICS, INC.
Effective
2024-01-15
Filed
December 15, 2023, 6:59 PM ET
On December 13, 2023, Gyre Therapeutics, Inc. (the “Company”) appointed Dr. Han Ying as the Company’s Chief Executive Officer, effective January 15, 2024, to succeed Dr. Charles Wu, whose employment with the Company will terminate on such date pursuant to his retirement for health reasons.
Departed

Charles Wu

Chief Executive Officer
GYRE · GYRE THERAPEUTICS, INC.
Effective
2024-01-15
Successor
Han Ying
Filed
December 15, 2023, 6:59 PM ET
Dr. Charles Wu, whose employment with the Company will terminate on such date pursuant to his retirement for health reasons.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Han Ying was appointed as Chief Executive Officer at GYRE THERAPEUTICS, INC..

Action
appointed
Role
Chief Executive Officer
Exact text from the filing
On December 13, 2023, Gyre Therapeutics, Inc. (the “Company”) appointed Dr. Han Ying as the Company’s Chief Executive Officer, effective January 15, 2024, to succeed Dr. Charles Wu, whose employment with the Company will terminate on such date pursuant to his retirement for health reasons.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Charles Wu retired as Chief Executive Officer at GYRE THERAPEUTICS, INC..

Action
retired
Role
Chief Executive Officer
Exact text from the filing
Dr. Charles Wu, whose employment with the Company will terminate on such date pursuant to his retirement for health reasons.
View on SEC.gov

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR
accession 0001140361-23-057889
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.